Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including patients with lupus nephritis.
The company said that, among evaluable lupus nephritis patients, 50%
These two Canadian dividend stocks offer a great mix of essential businesses, regular dividends, and long-term growth investments that could make them appealing retirement holdings for years to come.
Brixmor Property Group (NYSE:BRX) said it has entered definitive agreements with Everview Partners to acquire Slate Grocery REIT, a Canadian-listed owner of U.S. grocery-anchored shopping centers, in a transaction valued at $2.34 billion.
Under the transaction structure, Brixmor will directly acqui
While many investors overlook Nio's "other sales" segment, it's quickly becoming a huge storyline of its own -- and now its margins have turned positive.
IWO dominates in liquidity and assets under management, while ISCG offers a leaner fee structure and stronger dividend yield. Sector weightings and portfolio composition differ significantly between the two.
Zymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business.
Management said the transaction represent
Both Lucid and Stellantis have been significantly sold off, but if their turnarounds make a financial impact in the near term, investors could be positioned for big returns over the next five years.
